Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland. Sanna.K.Pakkanen@uta.fi
PALB2 1592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB2 1592delT mutation.
Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463).
From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB2 1592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype.
Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.
Notes
Cites: Cancer Res. 2001 Aug 15;61(16):6038-4111507049
Cites: Nat Genet. 2001 Feb;27(2):172-8011175785
Cites: Nat Genet. 2007 Feb;39(2):165-717200668
Cites: MedGenMed. 2005;7(2):6016369438
Cites: Mol Cell. 2006 Jun 23;22(6):719-2916793542
Cites: Curr Biol. 2009 Mar 24;19(6):524-919268590
Cites: Nature. 2007 Mar 15;446(7133):316-917287723
Cites: Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6788-9317420451
Cites: BJU Int. 2007 Jun;99(6):1350-517419707
Cites: J Natl Cancer Inst. 2007 Jun 20;99(12):929-3517565157
Cites: Cancer Causes Control. 2001 Oct;12(8):739-4611562114
Cites: Nat Genet. 2002 Feb;30(2):181-411799394
Cites: Am J Hum Genet. 2002 May;70(5):1299-30411941539
Cites: Nat Genet. 2002 Oct;32(2):321-512244320
Cites: Am J Hum Genet. 2003 Jan;72(1):1-1212474142
Cites: J Med Genet. 2003 Aug;40(8):e9812920090
Cites: Science. 2003 Oct 24;302(5645):643-614576434
Cites: Br J Cancer. 2003 Nov 17;89(10):1966-7014612911
Cites: Clin Cancer Res. 2003 Nov 1;9(14):5252-614614006
Cites: Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R103-2114749351
Cites: Prostate. 1990;16(1):39-481689482
Cites: J Med Genet. 1993 Oct;30(10):857-658230163
Cites: J Mol Med (Berl). 1997 Oct;75(10):758-619383000
Cites: Clin Cancer Res. 1999 Jun;5(6):1275-910389909
Cites: J Natl Cancer Inst. 2007 Dec 19;99(24):1881-718073376
Cites: Prostate. 2008 May 1;68(6):675-818288683
Cites: Breast Cancer Res Treat. 2009 Feb;113(3):545-5118302019